Targeting inflammation at its source.
Inflazome was a Dublin-based biotech company developing orally available small molecule NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases including Parkinson's, Alzheimer's, arthritis, and cardiovascular conditions. Founded in 2016 by Prof. Matt Cooper and Prof. Luke O'Neill, the company advanced two clinical-stage drugs before being acquired by Roche for €380 million in 2020.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountNov 2018
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
Healthcare company applying technology to drug development by building nimble biotech subsidiarie...
Neuralink is building a brain-computer interface for medical needs and greater human potential.
